BSI-082 alone or with T-DXd for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, BSI-082, alone or with another drug (T-DXd), for people with advanced solid tumors that no longer respond to standard therapy. It aims to find the best dose and check how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have an advanced or metastatic solid tumor that standard treatments have not helped or are not suitable.
- You must be willing to use effective birth control during the study and for 10 months after treatment ends, unless you or your partner are sterile or postmenopausal.
- Your heart, blood counts, liver, and kidneys need to be working at a certain level, and you must have at least one measurable tumor on scan.
- You cannot have had prior treatment with a CD47 or SIRPα-targeting drug, or have an active autoimmune disease needing immune-suppressing medicines.
- You cannot have uncontrolled infections, active hepatitis B or C, or untreated brain metastases, or a history of severe lung disease.
- You must not have taken a live vaccine within 30 days before starting the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for people with advanced solid tumors that have HER2 changes. The goal is to see if it can shrink tumors or slow growth.
This trial tests a new drug called BGB-26808, either by itself or with another drug called tislelizumab, for people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This study tests a new drug (DS5361b) for people with advanced solid tumors that have high genetic instability (TMB-H or MSI-H). It aims to see if the drug can shrink tumors or slow their growth.
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
This trial tests a new drug called BT02 for people with advanced solid tumors who have not had any cancer treatment before. It aims to see if BT02 is safe and how well it works.
This trial tests a new drug, D3L-002, for people with advanced solid tumors that have stopped responding to at least one prior treatment or have no standard options. The goal is to see if it can help shrink or control the cancer.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.